ARIScience provides molecular discovery and design services, including drug repositioning and de-novo molecular design. It integrates high-performance computing with quantum physics, biochemistry, computer vision, and AI to accelerate the drug discovery process.
Funding
Funding not disclosed
Founders
Product
Problem
Traditional drug discovery methods are time-consuming and expensive, often failing to identify effective drug candidates due to the complexity of biological systems and the limitations of conventional screening techniques. Identifying molecules that effectively interrupt disease pathways requires navigating vast chemical spaces and accurately predicting molecular interactions.
Solution
ARIScience offers molecular discovery and design services, leveraging an AI+QQ platform that integrates artificial intelligence, quantum chemistry, computer vision, and biochemistry to accelerate the identification of promising drug candidates. The platform predicts and constructs organic compounds capable of directly or allosterically interrupting proteins in biological pathways. ARIScience's approach combines in silico methodologies with in vitro and in vivo assays to validate and optimize compounds, focusing on treatments for neurodegenerative, inflammatory, and infectious diseases. The company's computation-first approach and diverse team of experts facilitate efficient iteration and refinement of drug candidates, increasing success rates and reducing the time to societal impact.
Target Audience
ARIScience primarily targets pharmaceutical companies and research institutions seeking to accelerate drug discovery and identify novel therapeutics for prevalent diseases.
Features
- AI+QQ platform integrating AI, quantum chemistry, computer vision, and biochemistry
- In silico methodology for predicting and constructing organic compounds
- Capability to design molecules that interrupt proteins allosterically, directly, or formatively
- In vitro assays for confirming in silico results
- In vivo confirmation using small animal models
- ARICore and BioTD technology assets to support the AI+QQ process